

Induction Healthcare Group PLC
("Induction", the "Company", or the "Group")

Grant of Options

London, UK- 17 July 2024: Induction Healthcare Group PLC(AIM: INHC)a leading digital health platform driving the transformation of healthcare systems, announces that following the announcement of the FY24 results and having met the criteria for the granting of options, on 15 July 2024 it granted, in aggregate, 850,000 options to Paul Tambeau (Chief Executive Officer) and John McIntosh (Chief Financial Officer) under the Company's Non-Tax Advantaged Share Option Plan.

The Options have an exercise price of 0.5 pence (equivalent to the nominal value of the Ordinary Shares) and, began vesting on 5 July 2024. 33.33% of the Options shall vest on the 5 July 2025, following which equal portions shall vest every three months across a twenty-four-month period.

Following this grant of Options, Induction has 2,400,000 Options in issue, representing approximately 2.56 per cent. of the Company's issued share capital.

Enquiries

Induction	
Christopher Samler, Chair	+44 (0)7712 194092
Paul Tambeau, Chief Executive Officer	+44 (0)7983 104443
Singer Capital Markets (Nominated Adviser and Broker)	+44 (0)20 7496 3000
Philip Davies	
Alaina Wong	
Finn Gordon	

About Induction - www.inductionhealthcare.com

Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.

Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated	
a.	Name	1. Paul Tambeau - Chief Executive Officer 2. John McIntosh - Chief Financial Officer
2.	Reason for the notification	
a.	Position/status	As above.
a.	Initial notification /Amendment	Initial notification

3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor										
a.	Name	Induction Healthcare Group PLC									
b.	LEI	213800RY96GCZQW5TP19									
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted										
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 0.5 pence each GB00BJ0M3545									
b.	Nature of the transaction	Grant of share options									
c.	Price(s) and volume(s)	<table> <tr> <td>PDMR</td> <td>Volume(s)</td> <td>Price(s)</td> </tr> <tr> <td>1. Paul Tambeau</td> <td>500,000</td> <td>Nominal Value</td> </tr> <tr> <td>2. John McIntosh</td> <td>350,000</td> <td>Nominal Value</td> </tr> </table>	PDMR	Volume(s)	Price(s)	1. Paul Tambeau	500,000	Nominal Value	2. John McIntosh	350,000	Nominal Value
PDMR	Volume(s)	Price(s)									
1. Paul Tambeau	500,000	Nominal Value									
2. John McIntosh	350,000	Nominal Value									
d.	Aggregated information Aggregated volume Price	N/A - single transactions									
e.	Date of the transaction	15-07-24									
f.	Place of the transaction	Off-Exchange									



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBLGDRRUBDGSL